Showing 3391-3400 of 5773 results for "".
- Alcon to Showcase Innovations for Eye Care Practice Success at 2023 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-innovations-for-eye-care-practice-success-at-2023-optometrys-meeting/2481682/Alcon will showcase innovations from advances in the reusable lens space to digital offerings at Optometry’s Meeting, the American Optometric Association (AOA) annual conference taking place June 21-24 in Washington, D.C. Through interactive events, Q&A’s, live demonstrations, and
- BVI launches Finevision HP Trifocal IOL in Japanhttps://modernod.com/news/bvi-launches-finevision-hp-trifocal-iol-in-japan/2481681/BVI has announced the launch of the Finevision HP hydrophobic and glistening free trifocal IOL in Japan. BVI Japan will host the official launch event at the upcoming Japanese Society of Cataract and Refractive Surgeons (JSCRS) annual meeting in Sapporo, Japan, June 22-24. Dr. Kazu
- New Analysis From N-MOmentum Clinical Trial of Uplinza Demonstrate Process that Could Improve Clinical Care Process for NMOSDhttps://modernod.com/news/new-analysis-from-n-momentum-clinical-trial-of-uplinza-demonstrate-process-that-could-improve-clinical-care-process-for-nmosd/2481680/Horizon Therapeutics announced the publication of a new analysis from the N-MOmentum clinical trial of Uplinza demonstrating the utility of an adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consiste
- Marinomed Biotech to Launch Carragelose Eye Drops in Europe in 2024https://modernod.com/news/marinomed-biotech-to-launch-carragelose-eye-drops-in-europe-in-2024/2481677/Marinomed Biotech announced it plans to introduce a new Carragelose eye drop product (MAM-1001-3) with an expected market launch in Austria targeted for the first half of 2024. Marinomed said it has started a business development process to identify partners for the marketing of the product
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis-1/2481676/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE-2 clinical trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational new drug, in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for t
- Zeiss Unveils Disposable Warm Eye Maskshttps://modernod.com/news/zeiss-unveils-disposable-zeiss-warm-eye-masks/2481674/Zeiss announced the release of Zeiss Warm Eye Masks, individually wrapped and disposable masks designed to refresh and soothe dry, tired eyes. The masks use gentle heat to soothe, relax and stimulate the oil glands (meibomian glands) in eyelids. The warmth helps to unbloc
- Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United Stateshttps://modernod.com/news/bausch-lomb-launches-preservision-areds-2-formula-soft-gels-plus-coq10-in-the-united-states/2481667/Bausch + Lomb announced the US launch of PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10). Developed as a two-in-one option, Bausch + Lomb says PreserVision AREDS 2 Formula eye vitamins plus CoQ10 is the only eye vitamin that combines the exact nutrient formula
- Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptorhttps://modernod.com/news/reduction-of-eyedrop-volume-for-topical-ophthalmic-medications-with-the-nanodropper-bottle-adaptor/2481663/Nanodropper announced positive results from a research study conducted in collaboration with Leonard Seibold, MD, Professor of Ophthalmology at University of Colorado School of Medicine, which quantified eyedrop volume reduction and bottle life extension with the Nanodropper adaptor compared
- New Data Published from Phase 3 N-MOmentum Trial of Horizon's Uplinzahttps://modernod.com/news/new-data-from-phase-3-n-momentum-trial-of-horizons-uplinza-published/2481660/Horizon Therapeutics announced the publication of new data from the Phase 3 N-MOmentum pivotal trial of Uplinza. The data offer insights on serum biomarkers that signal acute attacks and disability worsening associated with NMOSD and illustrate the role of Uplinza in reducing these biom
- Cellusion Raises $21 Million to Advance iPS Cell-Derived Corneal Endothelial Cell Substitutehttps://modernod.com/news/cellusion-raises-21-million-to-advance-ips-cell-derived-corneal-endothelial-cell-substitute/2481659/Tokyo-based Cellusion announced that it has raised 2.83 billion yen ($21 million USD) in Series C Round financing. The funding will be used to promote its lead program—the development of iPS cell-derived corneal endothelial cell substitute (CLS001) to resolve the challenge of